Three drugs of this class (palbociclib, ribociclib, and abemaciclib) have changed the treatment algorithm for advanced or metastatic estrogen receptor-positive BC and have been incorporated into clinical practice in many countries following robust improvements in progression-free survival rates (28). The gene discussed is ESR1; the disease is breast cancer.